Dietrich John Pauls - 10 Aug 2026 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship: President & CEO, Director
Issuer ticker: DMAC
Reported as of: 10 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:23:41 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua L. Colburn, attorney-in-fact

Key filing fact

Dietrich John Pauls filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 12 Aug 2026.

Key facts

This page summarizes Dietrich John Pauls's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 16:23.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001760123 Primary reporting owner

Pauls Dietrich John

Relationship: President & CEO, Director
Address: 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
Signature: /s/ Joshua L. Colburn, attorney-in-fact
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC transaction

Voting Common Shares, no par value per share

Award

Transaction value
Shares: +60,200
Change %: +88%
Price: $0.000000^*
Shares after: 128,791
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.

Footnote F2

Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.